

Neurotech

30 September 2020

Completion of Acquisition

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") is pleased to advise that a Biotechnology Licence Deed for the Company's exclusive worldwide licence to use proprietary cannabis strains for medicinal use in treating autism, epilepsy and ADHD (Refer ASX Release dated 3 July 2020) has been executed.

This represents the last condition precedent for completion of the acquisition by NTI of its rights to the cannabis strains, and the acquisition has now completed.

The Company has today issued 73,349,127 Shares and 38,000,000 NTIOPT8 Options (\$0.010, 31/01/2023) pursuant to its Prospectus dated 26 August 2020 which has now closed.

Following the issue of the above Securities, the Company's issued capital is as follows:

Type of Securities	Total Number of Securities
<u>Shares</u>	
NTI Fully Paid Ordinary Shares	388,564,756
<u>Options</u>	
NTIO Listed Options (\$0.06, 31/03/2021)	26,122,966
NTIOPT1 Options (\$0.20, 30/11/2020)	10,894,390
NTIOPT3 Options (\$0.0189, 18/11/2022)	10,000,000
NTIOPT4 Options (\$0.0589, 18/11/2024)	6,500,000
NTIOPT5 Options (\$0.0199, 18/11/2024)	5,429,754
NTIOPT6 Options (\$0.0084, 31/01/2023)	3,987,832
NTIOPT7 Options (\$0.005, 31/01/2023)	75,483,928
NTIOPT8 Options (\$0.010, 31/01/2023)	38,000,000

Authority

This announcement has been authorised for release by the Board of the Company.

Further Information

Mark Davies
Chairman
md@1861capital.com.au
+61 413137887

Winton Willesee
Non-Executive Director
winton@azc.com.au

Neurotech International Ltd
ABN 73 610 205 402
Suite 5 CPC, 145 Stirling Highway
Nedlands, Western Australia 6009
www.neurotechinternational.com

+61 410 667 844

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on facilitating the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Neurotech International Ltd

ABN 73 610 205 402

Suite 5 CPC, 145 Stirling Highway

Nedlands, Western Australia 6009

www.neurotechinternational.com